

DATE RAPE DRUGS

HEARING
BEFORE THE
SUBCOMMITTEE ON
OVERSIGHT AND INVESTIGATIONS
OF THE
COMMITTEE ON COMMERCE
HOUSE OF REPRESENTATIVES

ONE HUNDRED SIXTH CONGRESS

FIRST SESSION

MARCH 11, 1999

Serial No. 106-7

Printed for the use of the Committee on Commerce



U.S. GOVERNMENT PRINTING OFFICE

55-638CC

WASHINGTON : 1999

COMMITTEE ON COMMERCE

TOM BLILEY, Virginia, *Chairman*

W.J. "BILLY" TAUZIN, Louisiana	JOHN D. DINGELL, Michigan
MICHAEL G. OXLEY, Ohio	HENRY A. WAXMAN, California
MICHAEL BILIRAKIS, Florida	EDWARD J. MARKEY, Massachusetts
JOE BARTON, Texas	RALPH M. HALL, Texas
FRED UPTON, Michigan	RICK BOUCHER, Virginia
CLIFF STEARNS, Florida	EDOLPHUS TOWNS, New York
PAUL E. GILLMOR, Ohio	FRANK PALLONE, Jr., New Jersey
<i>Vice Chairman</i>	SHERROD BROWN, Ohio
JAMES C. GREENWOOD, Pennsylvania	BART GORDON, Tennessee
CHRISTOPHER COX, California	PETER DEUTSCH, Florida
NATHAN DEAL, Georgia	BOBBY L. RUSH, Illinois
STEVE LARGENT, Oklahoma	ANNA G. ESHOO, California
RICHARD BURR, North Carolina	RON KLINK, Pennsylvania
BRIAN P. BILBRAY, California	BART STUPAK, Michigan
ED WHITFIELD, Kentucky	ELIOT L. ENGEL, New York
GREG GANSKE, Iowa	THOMAS C. SAWYER, Ohio
CHARLIE NORWOOD, Georgia	ALBERT R. WYNN, Maryland
TOM A. COBURN, Oklahoma	GENE GREEN, Texas
RICK LAZIO, New York	KAREN McCARTHY, Missouri
BARBARA CUBIN, Wyoming	TED STRICKLAND, Ohio
JAMES E. ROGAN, California	DIANA DeGETTE, Colorado
JOHN SHIMKUS, Illinois	THOMAS M. BARRETT, Wisconsin
HEATHER WILSON, New Mexico	BILL LUTHER, Minnesota
JOHN B. SHADEGG, Arizona	LOIS CAPPS, California
CHARLES W. "CHIP" PICKERING, Mississippi	
VITO FOSSELLA, New York	
ROY BLUNT, Missouri	
ED BRYANT, Tennessee	
ROBERT L. EHRLICH, Jr., Maryland	

JAMES E. DERDERIAN, *Chief of Staff*

JAMES D. BARNETTE, *General Counsel*

REID P.F. STUNTZ, *Minority Staff Director and Chief Counsel*

SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS

FRED UPTON, Michigan, *Chairman*

JOE BARTON, Texas	RON KLINK, Pennsylvania
CHRISTOPHER COX, California	HENRY A. WAXMAN, California
RICHARD BURR, North Carolina	BART STUPAK, Michigan
<i>Vice Chairman</i>	GENE GREEN, Texas
BRIAN P. BILBRAY, California	KAREN McCARTHY, Missouri
ED WHITFIELD, Kentucky	TED STRICKLAND, Ohio
GREG GANSKE, Iowa	DIANA DeGETTE, Colorado
ROY BLUNT, Missouri	JOHN D. DINGELL, Michigan,
ED BRYANT, Tennessee	(Ex Officio)
TOM BLILEY, Virginia, (Ex Officio)	

(II)

CONTENTS

	Page
Testimony of:	
Adatsi, Felix, Toxicology Unit, Michigan State Police	39
Bane, Paul, Drug Enforcement Command, Maryland State Police	38
Dyer, Jo Ellen, Assistant Clinical Professor of Pharmacy, University of California at San Francisco Bay Area Regional Poison Control Center ..	34
Engel, Patti, Orphan Medical, Inc	88
Faistenhammer, G. Mark, Detective, Grosse Ile Police Department	26
Jackson-Lee, Hon. Sheila, a Representative in Congress from the State of Texas	13
Maher, Patricia L., Civil Division, Department of Justice	54
Porrata, Trinka, D., designer drug consultant	29
Pruett, Candace, accompanied by Lugene Pruett, Commonwealth of Vir- ginia	24
Reuter, Nicholas, Associate Director, Domestic and International Drug Control Office of Health Affairs, Food and Drug Administration	66
Snyder, Denise, DC Rape Crisis Center	42
Woodworth, Terrance W., Deputy Director, Office of Diversion Control, Drug Enforcement Administration	58
Zukin, Stephen, Director, Clinical and Services Research, National Insti- tute on Drug Abuse, National Institutes of Health	73
Material submitted for the record by:	
Meyers, Abbey S., President, National Organization for Rare Disorders, prepared statement of	99
Plaisier, Melinda, Interim Associate Commissioner for Legislative Affairs, Department of Health & Human Services, letter dated April 27, 1999, enclosing response for the record	100

(III)

DATE RAPE DRUGS

THURSDAY, MARCH 11, 1999

HOUSE OF REPRESENTATIVES,
SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS,
COMMITTEE ON COMMERCE,
Washington, DC.

The subcommittee met, pursuant to notice, at 9:30 a.m. in room 2322, Rayburn House Office Building, Hon. Fred Upton (chairman) presiding.

Members present: Representatives Upton, Burr, Whitfield, Bryant, Bliley (ex officio), Klink, Stupak, Green, McCarthy, Strickland, DeGette, and Dingell (ex officio).

Staff present: Alan Slobodin, majority counsel; Chuck Clapton, majority counsel; Jason C. Foster, legislative clerk; and Chris Knauer, minority investigator.

Mr. UPTON. Welcome, everyone. Today this subcommittee will hear testimony and gather facts on a growing public health and safety problem, so-called date rape drugs.

I want to particularly thank full committee Chairman Tom Bliley for supporting this hearing. I also want to recognize and thank our colleagues Sheila Jackson-Lee and Bart Stupak for their early leadership that they have shown on this issue, and our ranking member, Ron Klink, for his genuine concern that I know he shares about this growing problem.

The reality of this problem hit me hard several weeks ago when I heard about what happened to two young women in my home State of Michigan. While they were at a party, their beverages were laced with GHB, probably without their knowledge. Tragically, 15-year-old Samantha Reid and her friend lapsed into a coma, and Samantha died.

I am the father of an 11-year-old daughter, and I can only imagine what Samantha's family and friends have endured, and I want to join with Sheila Jackson-Lee and Bart Stupak for what I hope every member of this subcommittee today will do in committing themselves to doing whatever they can to prevent tragedies like this from occurring in the future, for I cannot imagine a worse nightmare for any parent.

What are date rape drugs? Date rape drugs are a popular reference to lethal street drugs that people may use to get high or to incapacitate women and make them utterly vulnerable to sexual assault. These drugs can induce a deep, anesthetic-type sleep.

We know many drugs are used to facilitate rape, but the most commonly encountered drugs in drug-facilitated rapes are GHB, Ketamine, and Flunitrazepam. The victim blacks out, experiences

(1)

amnesia, and by the time the victim wakes up and gets to the hospital, it may be too late to detect even the presence of the drug because the drug moves so rapidly through their system.

I want to clarify that date rape drugs are in many cases a misnomer. They may be used by near strangers or others to incapacitate young women.

A few years ago, Rohypnol, a prescription anesthetic drug sold in many foreign countries, was the leading date rape drug. Thanks to restrictions on its import, Federal controls and changes that the manufacturer made to it makes it less easy now to abuse it as a date rape drug. Rohypnol no longer is a big part of the problem. Now it is GHB, and to some extent Ketamine, which are the leading date rape drugs.

What makes GHB a particularly fast-growing problem is the availability of its ingredients: hundreds of Internet sites. In fact, we have an example here, a demonstration. Maybe if we can just dim the lights? Darlene, can you just—thanks.

Hundreds of Internet websites promoting GHB and others offer ingredient kits and recipes for making it and the difficulty in detecting this drug. Neither GHB nor Ketamine is under Federal control.

The DEA has documented over 3,500 overdoses in law enforcement encounters with GHB and more than 32 GHB-related deaths since 1990. According to the Drug Abuse Warning Network, GHB-related hospital emergency department episodes increased from 20 in 1992 to 629 in 1996. Clearly the status quo is entirely unacceptable.

In today's hearing, I want us to focus on what additional steps should and could be taken at the Federal and State levels to protect our vulnerable young people from the vile misuse of these substances.

We have impressive witnesses to assist the subcommittee with its fact finding. We will hear first from Sheila Jackson-Lee, our colleague from Texas, who has introduced legislation in response to the death of a 17-year-old girl in her district who died as a result of unintentionally drinking GHB, which was poured into her soft drink. I look forward to working with Congresswoman Sheila Jackson-Lee on this issue and others.

We will then hear from a panel of witnesses offering various perspectives on the problem. Those perspectives will be those from victims, victim advocates, law enforcement and the medical community. We will hear from experts representing the Department of Justice, DEA, the Food and Drug Administration and the National Institute on Drug Abuse.

Finally, we will hear from Orphan Medical, Inc., a company developing a GHB derivative drug in clinical trials for the terribly debilitating symptom of narcolepsy. They are concerned that if GHB was scheduled as a I or II drug, it would be impossible for them to continue their research.

I appreciate the support of my colleague, Ron Klink, for holding this hearing, and I look forward to working with him and everyone else on this issue, and I will, in his stead as acting ranking member of the subcommittee, recognize Bart Stupak for an opening statement.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.